Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Regeneron Pharmaceuticals, Inc. (REGN) AI Forecast

Our AI ranks Regeneron Pharmaceuticals, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$REGN Bearish Signal Full forecast available

Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast Sept. 24, 2026


Regeneron Pharmaceuticals, Inc. (REGN) AI Stock Price Forecast & Investment Analysis

Regeneron Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Regeneron Pharmaceuticals, Inc. (REGN) - Comprehensive Stock Analysis & Investment Research

Deep dive into Regeneron Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Regeneron Pharmaceuticals, Inc. Investment Summary

When evaluating whether Regeneron Pharmaceuticals, Inc. (REGN) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Regeneron Pharmaceuticals, Inc. (REGN) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $83 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Regeneron Pharmaceuticals, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Regeneron Pharmaceuticals, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Regeneron Pharmaceuticals, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Regeneron Pharmaceuticals, Inc.

Sign Up Free
Corporate Identity

Regeneron Pharmaceuticals, Inc. (Stock Symbol: REGN) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Regeneron Pharmaceuticals, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Regeneron Pharmaceuticals, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Regeneron Pharmaceuticals, Inc....

Unlock Full Company Profile

Get complete details about Regeneron Pharmaceuticals, Inc.

Sign Up Free
Revenue & Growth Analysis

Regeneron Pharmaceuticals, Inc. generates annual revenues of $16 billion , demonstrating substantial market presence and operational scale.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Regeneron Pharmaceuticals, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Regeneron Pharmaceuticals, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Regeneron Pharmaceuticals, Inc....

Unlock Financial Analysis

Get complete financial metrics for Regeneron Pharmaceuticals, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Regeneron Pharmaceuticals, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Regeneron Pharmaceuticals, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Regeneron Pharmaceuticals, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company demonstrates exceptional operational efficiency through free cash flow generation of $4 billion annually , with year-over-year cash flow growth of -1.3%. This substantial cash generation capability provides significant strategic flexibility for acquisitions, share repurchases, dividend growth, or debt reduction—all while maintaining operational investments necessary to defend market position.

Asset Utilization Efficiency

Asset turnover ratio of 0.37x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 3.34 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Regeneron Pharmaceuticals, Inc. (REGN) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Regeneron Pharmaceuticals, Inc. stock analysis. Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.

Deep dive into Regeneron Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Regeneron Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Regeneron Pharmaceuticals, Inc.: With a P/E ratio of 19.07, the market moderately values the company's earnings.

P/E Ratio 19.07x
P/B Ratio 2.60x
Market Cap $82.55B
Dividend Yield 0.46%
EPS $40.38
Book Value/Share $308.01
Revenue/Share $150.89
FCF/Share $36.52
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Regeneron Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Regeneron Pharmaceuticals, Inc.:

ROIC 10.6%
Operating Margin 50.7%
EBT Margin 68.1%
Tax Rate 16.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Regeneron Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Regeneron Pharmaceuticals, Inc.: A current ratio of 3.34 indicates strong liquidity.

Current Ratio 3.34x
Quick Ratio 2.78x
D/E Ratio 0.32x
Financial Leverage 1.32x
Interest Coverage 21.2x
Working Capital $12.92B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Regeneron Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Regeneron Pharmaceuticals, Inc.: Free cash flow of $3760M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $4.68B
Free Cash Flow $3.76B
Capital Spending -$921M
OCF Growth YoY -1.3%
FCF Growth YoY -2.4%
FCF/Sales 24.2%
CapEx/Sales 5.9%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Regeneron Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Regeneron Pharmaceuticals, Inc.: An asset turnover of 0.37x suggests room for improvement in asset utilization.

Asset Turnover 0.37x
Receivables Turnover 2.4x
Fixed Assets Turnover 2.9x
Days Sales Outstanding 154 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Regeneron Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Regeneron Pharmaceuticals, Inc.: With annual revenue of $15534M, Regeneron Pharmaceuticals, Inc. operates at significant scale.

Income Statement
Total Revenue $15.53B
Operating Income $3.84B
R&D Expense $6.28B
SG&A Expense $2.74B
Balance Sheet Highlights (USD millions)
Total Current Assets $18.45B (44.2% of assets)
Cash & Short-term Investments $2.46B (5.9% of assets)
Accounts Receivable $6.57B (15.7% of assets)
Inventory $3.08B (7.4% of assets)
Total Liabilities $10.02B (24.0% of assets)
Short-term Debt $4.37B (10.5% of assets)
Dividend & Shareholder Information
Dividends Per Share $3.68
Payout Ratio 9.1%
Shares Outstanding 103M

Latest Regeneron Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Regeneron Pharmaceuticals, Inc. (REGN) stock price and investment outlook.

More news available

Sign up free to read all 10 news articles and stay updated on market developments.

Sign Up Free to Read More

Where REGN sits on the market map

Explore the map →

Regeneron Pharmaceuticals, Inc. Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Regeneron Pharmaceuticals, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
REGN ██% $82.55B 19.1x 2.6x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Regeneron Pharmaceuticals, Inc. Stock Forecast

How accurate are Regeneron Pharmaceuticals, Inc. stock predictions?

A per-ticker accuracy statistic for REGN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Regeneron Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Regeneron Pharmaceuticals, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Regeneron Pharmaceuticals, Inc. a good investment in 2026?

Based on our AI analysis, Regeneron Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Regeneron Pharmaceuticals, Inc. forecasts updated?

Regeneron Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Regeneron Pharmaceuticals, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...